GlassScriptPhysician profile
Geethu T James
NPI 1710564794
$1,381.20
in general payments reported to CMS, 2019-2025
15 companies · $816 in 2025
The $816 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $565 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $385.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals LP | $336.75 | 2024-2025 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $117.05 | 2024 | Voquezna |
| Novo Nordisk INC | $105.98 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $97.62 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $84.67 | 2024-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $43.84 | 2025 | |
| Xeris Pharmaceuticals, INC. | $42.23 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $39.30 | 2025 | |
| Hologic Sales and Service, LLC | $26.67 | 2025 | Aptima |
| Abbott Laboratories | $22.50 | 2025 | Freestyle Libre |
| Dexcom, INC. | $21.07 | 2024 | Dexcom G6 Transmitter |
| Optinose US, INC. | $20.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.94 | 2024 | |
| Glaxosmithkline, LLC. | $18.58 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geethu James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.